Long-acting betamimetics for the treatment of respiratory complaints

1) A compound of formula 1,

• wherein
• n denotes 1, 2, 3 or 4;
• A denotes a double-bonded group selected from among —O, —CR4R5, —NR6, —S, —CR4R5—O, —CR4R5—NR6, —CH═CH or —CH2—CH2—;
• R1 denotes —C1-6-alkyl;
• R2 and R3, which may be identical or different, denote H, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-6-cycloalkyl, C1-6-haloalkyl, —O—C1-6-haloalkyl, halogen, OH, CN, NO2, O—C1-6-alkyl, —C2-6alkyl-OH, NH2, NH—C1-6-alkyl, N(C1-6-alkyl)2, NHCO—C1-6-alkyl, NHSO2—C1-6-alkyl, S—C1-6-alkyl, SO—C1-6-alkyl, SO2—C1-6-alkyl, SO2NH2, SO2NH—C1-6-alkyl, SO2N(C1-6-alkyl)2, CONH2, CONH—C1-6-alkyl, CON(C1-6-alkyl)2, —CO—C1-6-alkyl, COOH or COO—C1-4-alkyl, or
• R2 and R3 together denote a double-bonded group selected from —O—CR4R5—O, —O—CR4R5—NR6 or —CH═CH—CH═CH—;
• R4 denotes H or C1-6-alkyl;
• R5 denotes H or C1-6-alkyl;
• R6 denotes H or C1-6-alkyl,
• optionally in the form of an individual enantiomer thereof, a mixture of the individual enantiomers or a racemate, optionally in the form of a pharmacologically acceptable acid addition salt thereof, as well as optionally in the form of a solvate and/or a hydrate thereof.